TITLE

Maximizing REMS potential

AUTHOR(S)
Walker, Scot
PUB. DATE
September 2012
SOURCE
Drug Topics;Sep2012, Vol. 156 Issue 9, p24
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the need improve the potential of U.S. Food and Drug Administration's (FDA) Risk Evaluation and Mitigation Strategies (REMS) program. It informs about criticism of the REMS program, that was designed to address issues concerning drug safety and states that the FDA is planning to introduce of a standardized format for manufacturers. It recommends use of an electronic drug information technology that could help retail pharmacists to find drugs that match REMS criteria.
ACCESSION #
80035180

 

Related Articles

  • Impact of the FDA warning of potential ceftriaxone and calcium interactions on drug use policy in clinical practice. Esterly, John S.; Steadman, Emily; Scheetz, Marc H. // International Journal of Clinical Pharmacy;Jun2011, Vol. 33 Issue 3, p537 

    Objective In September 2007, the FDA issued an alert recommending that ceftriaxone and calcium-containing solutions should not be administered to any patient within 48 h of each other. Due to the widespread use of ceftriaxone, significant concern was expressed by the greater healthcare community...

  • Drug Warnings: Is My Medicine Safe?  // American Family Physician;2/1/2010, Vol. 81 Issue 3, p304 

    The article provides information on drug warnings that the U.S. Food and Drug Administration (FDA) releases when it is concerned over the safety of a medication. To alert patients and physicians about the serious adverse effects of a particular drug, the FDA reportedly utilized a so-called black...

  • Fast-forwarding APhA periodicals into the digital age. Posey, L. Michael // Pharmacy Today;Aug2011, Vol. 17 Issue 8, p4 

    An introduction is presented in which the editor discusses topics including the actions taken by the U.S. Food and Drug Administration (FDA), the print version of the "Journal of the American Pharmacists Association" (JAPhA) and APhA member's access to major clinal study or guideline.

  • FDA panel OKs expanded use for CRT-D.  // Cardiology Today;Jan2012, Vol. 15 Issue 1, p31 

    The article reports on the approval given by a U.S. Food and Drug Administration (FDA) panel to expand the use of Medtronic's cardiac resynchronization therapy defibrillator.

  • FDA panel recommendation creates mixed opinions about future of rosiglitazone. Kalvaitis, Katie // Hem/Onc Today;8/25/2010, Vol. 11 Issue 16, p41 

    This article deals with the questions raised by physicians on the future of rosiglitazone, a diabetic drug, about its future following a recommendation by the U.S. Food and Drug Administration (FDA) advisory committee that it stays on the U.S. market but with revised labeling and restrictions on...

  • FDA issues proposed rule, guidance for drug compounding under DQSA.  // AHA News;7/11/2014, Vol. 50 Issue 14, p2 

    The article reports that the U.S. Food and Drug Administration (FDA) released a proposal to add 25 items to its list of drug products that may not be compounded, a draft interim guidance for facilities that outsource compounded drugs, and a final guidance for entities intending to compound drugs.

  • Heparin Producers on Import Alert. Serebrov, Mari // BioWorld Today;2/27/2012, Vol. 23 Issue 38, p6 

    The article deals with the import alerts imposed by the U.S. Food and Drug Administration (FDA) in February 2012 on heparin and heparin-related products made by certain Chinese firms.

  • Public meeting about drug shortages planned by US FDA.  // PharmacoEconomics & Outcomes News;9/17/2011, Issue 637, p2 

    The article offers information on the U.S. Food and Drug Administration's (FDA) public workshop about drug shortages to be held on September 26, 2011.

  • FDA Rethinks Compounding Discretion.  // BioWorld Today;6/19/2012, Vol. 23 Issue 118, p8 

    The article focuses on the decision of the U.S. Food and Drug Administration (FDA) to reconsider its enforcement discretion with respect to compounded products, in response to a public protest in 2011 over an increase in pricing for the Makena hydroxyprogesterone caproate of KV Pharmaceutical Co.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics